BACKGROUND: Reduced physical activity is associated with increased morbidity and mortality in patients with COPD. Studies suggest that treatment with the long-acting muscarinic antagonist tiotropium and the long-acting β2-agonist olodaterol increases exercise capacity. This study assessed the effects of a fixed-dose combination (FDC) of tiotropium/olodaterol (delivered via Respimat®) on physical functioning in patients with stable COPD in a "real-world setting". METHODS: An international, open-label, single-arm, non-interventional study conducted in nine countries measuring changes in self-reported physical functioning in COPD patients treated with tiotropium/olodaterol 5/5 μg FDC for approximately 6 weeks. The primary endpoint was therapeutic success, defined as a minimum 10-point increase in the 10-question Physical Functioning Questionnaire (PF-10) score. Secondary endpoints included absolute change in PF-10 from Visit 1 to Visit 2, patient general condition (measured by Physician's Global Evaluation score) and patient satisfaction with the treatment and device (assessed by Patient Satisfaction Questionnaire at the end of the study period). RESULTS: Therapeutic success was observed in 67.8% of 7218 patients (95% CI 66.7, 68.8) in the final analysis set after approximately 6 weeks of treatment with tiotropium/olodaterol. Mean change in PF-10 score between Visit 1 and Visit 2 was 16.6 points (95% CI 16.2, 17.0). Therapeutic success was 64.3% (95% CI 63.0-65.6%) in patients with infrequent (≤1) and 76.1% (95% CI 74.3-77.9%) in patients with frequent (≥2) exacerbations (p<0.0001). Patient general condition improved as indicated by an improvement in Physician's Global Evaluation scores between visits. Most patients were very satisfied or satisfied with tiotropium/olodaterol treatment in general (81%), reported inhalation satisfaction (85%), and satisfactory handling of the device (84%). 1.3% of patients reported an investigator-defined drug-related adverse event. CONCLUSION: Treatment with tiotropium/olodaterol led to an improvement in self-reported physical functioning in patients with COPD.

Biostatistics and Data Sciences Boehringer Ingelheim Pharmaceuticals Inc Ridgefield CT USA

Department of Functional Diagnostics Specialized Hospital of Saint Zoerardus Teaching Facility of the Slovak Medical University Nitra Slovakia

Department of Internal Medicine Hebrew University Hadassah Medical School Jerusalem Israel

Department Of Pneumology Carol Davila University of Medicine and Pharmacy Bucharest Romania

Department of Pneumology Institute of Pneumatology Marius Nasta Bucharest Romania

Department of Pulmonology Pirogov Russian National Research Medical University Pletnev Hospital Moscow Russian Federation

Department of Respiratory and Critical Care Medicine Karl Landsteiner Institute for Lung Research and Pulmonary Oncology Krankenhaus Nord Klinik Floridsdorf Vienna Austria

Elizabeth Nursing Home Gödöllő Hungary

Lung Centre Pneumology Department University Hospital Basel Basel Switzerland

Medical Affairs Regional Center Boehringer Ingelheim RCV GmbH and Co KG Vienna Austria

Pneumological Outpatient Department MephaCentrum a s Ostrava Poruba Czech Republic

Respiratory TA Boehringer Ingelheim RCV GmbH and Co KG Vienna Austria

Topolšica Hospital Topolšica Slovenia

Zobrazit více v PubMed

World Health Organization. Chronic obstructive pulmonary disease (COPD). Available from: http://www.who.int/mediacentre/factsheets/fs315/en/ Accessed February19, 2018.

Rabe KF, Watz H. Chronic obstructive pulmonary disease. PubMed DOI

Bidan CM, Veldsink AC, Meurs H, Gosens R. Airway and extracellular matrix mechanics in COPD. PubMed DOI PMC

Casaburi R. Activity promotion: a paradigm shift for chronic obstructive pulmonary disease therapeutics. PubMed DOI

Corbridge SJ, Nyenhuis SM. Promoting physical activity and exercise in patients with asthma and chronic obstructive pulmonary disease. DOI

Troosters T, Sciurba F, Battaglia S, et al. Physical inactivity in patients with COPD, a controlled multi-center pilot-study. PubMed DOI PMC

Watz H, Waschki B, Meyer T, Magnussen H. Physical activity in patients with COPD. PubMed DOI

Gea J, Pascual S, Casadevall C, Orozco-Levi M, Barreiro E. Muscle dysfunction in chronic obstructive pulmonary disease: update on causes and biological findings. PubMed PMC

Pitta F, Troosters T, Probst VS, Spruit MA, Decramer M, Gosselink R. Quantifying physical activity in daily life with questionnaires and motion sensors in COPD. PubMed DOI

Ding B, Small M, Bergstrom G, Holmgren U. COPD symptom burden: impact on health care resource utilization, and work and activity impairment. PubMed DOI PMC

Laurin C, Moullec G, Bacon SL, Lavoie KL. Impact of anxiety and depression on chronic obstructive pulmonary disease exacerbation risk. PubMed DOI

Giardino ND, Curtis JL, Andrei AC, et al. Anxiety is associated with diminished exercise performance and quality of life in severe emphysema: a cross-sectional study. PubMed DOI PMC

Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M, Gosselink R. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. PubMed DOI

Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2018 report. Available from: https://goldcopd.org/gold-reports/ Accessed July17, 2018.

O’Donnell DE, Casaburi R, Frith P, et al. Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD. PubMed DOI PMC

Thomas M, Decramer M, O’Donnell DE. No room to breathe: the importance of lung hyperinflation in COPD. PubMed DOI PMC

O’Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. PubMed DOI

O’Donnell DE. Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. PubMed DOI

Maltais F, O’Donnell D, Galdiz Iturri JB, et al. Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease. PubMed DOI PMC

Troosters T, Maltais F, Leidy N, et al. Effect of bronchodilation, exercise training, and behavior modification on symptoms and physical activity in chronic obstructive pulmonary disease. PubMed DOI

Peeters G, Dobson A, Deeg D, Brown W. A life-course perspective on physical functioning in women. PubMed DOI PMC

Sauer R, Hansel M, Buhl R, Rubin RA, Frey M, Glaab T. Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study. PubMed PMC

Steinmetz K, Abenhardt B, Pabst S, et al. Physical functioning, general condition and satisfaction with tiotropium/olodaterol in real-world COPD patients in Germany. Abstract submitted to European Respiratory Society International Congress; 2018; Paris.

Boehringer Ingelheim Limited. Spiolto Respimat 2.5 microgram/2.5 microgram, inhalation solution – summary of product characteristics. Available from: https://www.medicines.org.uk/emc/medicine/30495 Accessed February28, 2018.

Hassan E. Recall bias can be a threat to retrospective and prospective research designs.

Althubaiti A. Information bias in health research: definition, pitfalls, and adjustment methods. PubMed DOI PMC

Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. PubMed DOI

Cohen J, editor.

Steinmetz K, Abenhardt B, Pabst S, et al. Assessment of physical functioning and handling of tiotropium/olodaterol Respimat PubMed DOI PMC

Rau-Berger H, Mitfessel H, Glaab T. Tiotropium Respimat PubMed DOI PMC

Global Initiative for Chronic Obstructive Lung Disease. GOLD 2017: global strategy for the diagnosis, management and prevention of COPD - Global Initiative for Chronic Obstructive Lung Disease (GOLD). Available from: http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/ Accessed September6, 2017.

Esteban C, Quintana JM, Aburto M, et al. Impact of changes in physical activity on health-related quality of life among patients with COPD. PubMed DOI

Waschki B, Kirsten A, Holz O, et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. PubMed DOI

Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). PubMed DOI PMC

Beeh KM, Westerman J, Kirsten AM, et al. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease. PubMed DOI

O’Donnell DE, Lam M, Webb KA. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. PubMed DOI

O’Donnell DE, Hamilton AL, Webb KA. Sensory-mechanical relationships during high-intensity, constant-work-rate exercise in COPD. PubMed DOI

Hohlfeld JM, Vogel-Claussen J, Biller H, et al. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. PubMed DOI

Ichinose M, Minakata Y, Motegi T, et al. Efficacy of tiotropium/olodaterol on lung volume, exercise capacity, and physical activity. PubMed DOI PMC

Zwerink M, van der Palen J, van der Valk P, Brusse-Keizer M, Effing T. Relationship between daily physical activity and exercise capacity in patients with COPD. PubMed DOI

Shioya T, Sato S, Iwakura M, et al. Improvement of physical activity in chronic obstructive pulmonary disease by pulmonary rehabilitation and pharmacological treatment. PubMed DOI

Borel B, Provencher S, Saey D, Maltais F. Responsiveness of various exercise-testing protocols to therapeutic interventions in COPD. PubMed DOI PMC

Bourbeau J, Lavoie KL, Sedeno M. Comprehensive self-management strategies. PubMed DOI

Celli B, Blasi F, Gaga M, et al. Perception of symptoms and quality of life – comparison of patients’ and physicians’ views in the COPD MIRROR study. PubMed DOI PMC

Miravitlles M, Ribera A. Understanding the impact of symptoms on the burden of COPD. PubMed DOI PMC

ZuWallack R, Allen L, Hernandez G, Ting N, Abrahams R. Efficacy and safety of combining olodaterol Respimat( PubMed DOI PMC

White DK, Wilson JC, Keysor JJ. Measures of adult general functional status: SF-36 Physical Functioning Subscale (PF-10), Health Assessment Questionnaire (HAQ), Modified Health Assessment Questionnaire (MHAQ), Katz Index of Independence in activities of daily living, Functional Independence Measure (FIM), and Osteoarthritis-Function-Computer Adaptive Test (OA-Function-CAT). PubMed

Eisner MD, Blanc PD, Yelin EH, et al. COPD as a systemic disease: impact on physical functional limitations. PubMed DOI PMC

Holt S, Sheahan D, Helm C, Tofield C, Corin A, Kocks JW. Little agreement in GOLD category using CAT and mMRC in 450 primary care COPD patients in New Zealand. PubMed DOI PMC

Kim S, Oh J, Kim YI, et al. Differences in classification of COPD group using COPD assessment test (CAT) or modified Medical Research Council (mMRC) dyspnea scores: a cross-sectional analyses. PubMed DOI PMC

Davis KJ, Landis SH, Oh YM, et al. Continuing to Confront COPD International Physician Survey: physician knowledge and application of COPD management guidelines in 12 countries. PubMed PMC

Miravitlles M, Andreu I, Romero Y, Sitjar S, Altes A, Anton E. Difficulties in differential diagnosis of COPD and asthma in primary care. PubMed DOI PMC

Bjornsdottir US, Sigurethardottir ST, Jonsson JS, et al. Impact of changes to reimbursement of fixed combinations of inhaled corticosteroids and long-acting beta(2) -agonists in obstructive lung diseases: a population-based, observational study. PubMed DOI PMC

Anzueto AR, Vogelmeier CF, Kostikas K, et al. The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD. PubMed DOI PMC

Greulich T, Kostikas K, Gaga M, et al. Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study. PubMed DOI PMC

Anzueto AR, Kostikas K, Mezzi K, et al. Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study. PubMed DOI PMC

Rogliani P, Calzetta L, Braido F, et al. LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review. PubMed DOI PMC

Alahmari AD, Kowlessar BS, Patel AR, et al. Physical activity and exercise capacity in patients with moderate COPD exacerbations. PubMed DOI

Pitta F, Troosters T, Probst VS, Spruit MA, Decramer M, Gosselink R. Physical activity and hospitalization for exacerbation of COPD. PubMed DOI

Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Antó JM. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. PubMed DOI PMC

Jones GL. Quality of life changes over time in patients with chronic obstructive pulmonary disease. PubMed DOI

Beeh KM, Burgel PR, Franssen FME, et al. How do dual long-acting bronchodilators prevent exacerbations of chronic obstructive pulmonary disease? PubMed DOI

Ariel A, Altraja A, Belevskiy A, et al. Inhaled therapies in patients with moderate COPD in clinical practice: current thinking. PubMed DOI PMC

Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. PubMed DOI

Boehringer Ingelheim. FDA approves Stiolto

Sievi NA, Brack T, Brutsche MH, et al. Accelerometer- versus questionnaire-based assessment of physical activity and their changes over time in patients with COPD. PubMed DOI PMC

Thyregod M, Bodtger U. Coherence between self-reported and objectively measured physical activity in patients with chronic obstructive lung disease: a systematic review. PubMed DOI PMC

Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. PubMed DOI PMC

Therapeutic Success of Tiotropium/Olodaterol, Measured Using the Clinical COPD Questionnaire (CCQ), in Routine Clinical Practice: A Multinational Non-Interventional Study